Tao Wan

机构：Jinan University, HiTec Marketing

发表论文 81 篇 · 总被引 1716 次 · h-index 23

代表论文

• Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial (2023 · Journal for ImmunoTherapy of Cancer · 被引 131)
• Construction and Validation of a Ferroptosis-Related lncRNA Signature as a Novel Biomarker for Prognosis, Immunotherapy and Targeted Therapy in Hepatocellular Carcinoma (2022 · Frontiers in Cell and Developmental Biology · 被引 52)
• Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review (2022 · BioScience Trends · 被引 35)
• Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability (2022 · Frontiers in Oncology · 被引 29)
• Comparison of survival benefit between salvage surgery after conversion therapy versus surgery alone for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis (2023 · HPB · 被引 21)
• Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma (2023 · World Journal of Surgical Oncology · 被引 12)